Rilonacept

Rilonacept

Clinical data
AHFS/Drugs.com	Monograph
License data	US FDA: Arcalyst
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Subcutaneous
ATC code	L04AC04 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name n/a
ChemSpider	none
UNII	8K80YB5GMG Y
ChEMBL	CHEMBL1201830 N
NY (what is this?)  (verify)

Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.^[1]

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.^[2]

Rilonacept was given an "Orphan Drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease(not approved in the U.S. on this indication).^[3]

On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.^[4]

References

External links

• Regeneron Pharmaceuticals home page